Cancer Treatment Reviews
Overview
Cancer Treatment Reviews is a reputable peer-reviewed journal that provides comprehensive and up-to-date reviews on various aspects of cancer treatment. It covers a wide range of topics, including novel therapies, clinical trials, emerging technologies, and personalized medicine, offering valuable insights to clinicians, researchers, and healthcare professionals involved in the field of oncology.
Details
Details
Abbr.
Cancer Treat Rev
Publisher
Elsevier
Start
1974
End
Continuing
Frequency
Six no. a year
p-ISSN
0305-7372
e-ISSN
1532-1967
Country
Netherlands
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 1178
164
SJR / Ranks: 426
3667
CiteScore / Ranks: 319
20.70
JIF / Ranks: 338
11.8
Recent Articles
1.
Petrelli F, Riboldi V, Bruschieri L, Villa A, Cribiu F, Borgonovo K, et al.
Cancer Treat Rev
. 2025 Mar;
135:102921.
PMID: 40086103
Introduction: Locally advanced cervical carcinoma (LACC) remains a significant global health issue, particularly in low- and middle-income countries (LMICs), where disease burden is highest. While cisplatin-based chemoradiotherapy (CTRT) has long...
2.
Delcuratolo M, Crespi V, Saba G, Mogavero A, Napoli V, Garbo E, et al.
Cancer Treat Rev
. 2025 Mar;
135:102918.
PMID: 40086102
Despite PACIFIC set a new milestone in the clinical management of unresectable stage III non-small cell lung cancer (NSCLC), it left some critical questions pending for clinical research: the efficacy...
3.
Szturz P, Fuereder T, Guo Y, Licitra L, Mesia R, Ivanyi P, et al.
Cancer Treat Rev
. 2025 Mar;
135:102910.
PMID: 40068239
Treatment options for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have evolved over the past decade and have helped improve survival outcomes...
4.
Galli E, Patelli G, Villa F, Gri N, Mazzarelli C, Mangoni I, et al.
Cancer Treat Rev
. 2025 Mar;
135:102908.
PMID: 40058162
Background: Relapse after radical treatment remains a major concern in hepatocellular carcinoma (HCC), affecting 50-75 % of early-stage cases within 5 years. Early recurrence prediction is a clinical unmet need....
5.
Georgopoulou S, Droney J, Jaganathan P, Howell P, Doherty A, Young K, et al.
Cancer Treat Rev
. 2025 Mar;
135:102862.
PMID: 40056766
Background: The implementation of patient-reported outcome measures (PROMs) in the clinical identification of immunotherapy toxicities is a complex intervention. There has been very little work evaluating the clinical utility and...
6.
Nguyen Van Long F, Poirier B, Desbiens C, Perron M, Paquet C, Ouellet C, et al.
Cancer Treat Rev
. 2025 Mar;
135:102909.
PMID: 40054315
Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) tumors represent the most common types of early-stage breast cancer. However, their response to adjuvant systemic treatments varies widely...
7.
Jeon M, DiSipio T, Wilson L, Garvey G, Diaz A
Cancer Treat Rev
. 2025 Mar;
135:102903.
PMID: 40054314
Background: Breast cancer patients are at increased risk of cardiovascular disease, which often are associated with cardiotoxic breast cancer treatment or overlapping risk factors between the two diseases. Pre-treatment cardiovascular...
8.
Berton Giachetti P, Carnevale Schianca A, Trapani D, Marra A, Toss A, Marchio C, et al.
Cancer Treat Rev
. 2025 Mar;
135:102887.
PMID: 40048856
Multigene prognostic genomic assays have become essential tools in the management of early breast cancer (BC), providing information that help in risk-stratification, to provide risk-adapted decision-making of adjuvant treatments. Clinical...
9.
Spada F, Rossi R, Modica R, Gelsomino F, Rinzivillo M, Rubino M, et al.
Cancer Treat Rev
. 2025 Mar;
135:102907.
PMID: 40023966
Introduction And Aims: Functioning neuroendocrine tumors (f-NETs) represent a minority of all NETs, however their management is challenging due to the impact on patients' survival and quality of life. In...
10.
Assi T, Moussa T, Ngo C, Faron M, Verret B, Levy A, et al.
Cancer Treat Rev
. 2025 Feb;
134:102904.
PMID: 40020639
Tenosynovial giant cell tumor is a non-malignant primary locally aggressive articular disease that affects the synovium of joints, tendon sheaths, and bursae. It is characterized by a translocation t (1;2),...